{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1891428068122037264.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"UCL - SSS/IREC/MONT - Pôle Mont Godinne"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1360580236934061312","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1056/nejmoa2115022"},{"@type":"URI","@value":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa2115022"},{"@type":"PMID","@value":"35732147"},{"@type":"HANDLE","@value":"11588/963505"},{"@type":"HANDLE","@value":"2078.1/280103"},{"@type":"HANDLE","@value":"11381/2919888"}],"notation":[{"@value":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer"}],"relation":[{"type":"contributor"}]}],"dataSourceIdentifier":[{"@type":"OPENAIRE","@value":"doi_dedup___::b546e51ec290c6b7ea098e477d903539_AsB0elYJFUMVjWk6JMaULQvIvsg_contributor"}]}